Send a question to the European Medicines Agency
Use this form to send a request for information from the European Medicines Agency (EMA) or to make a formal request for access to EMA documents that are not already published on this website.
For technical support with EMA's IT systems (e.g. Eudravigilance, IRIS, EudraCT), please see Assistance with information technology (IT) systems.
Read our Frequently asked questions before sending EMA a question. These provide answers to questions sent regularly to the Agency by its stakeholders, such as:
- What is the Agency responsible for?
- Are all medicines in the European Union approved via the Agency?
- How are herbal medicines evaluated?
- What are the responsibilities of the Agency in the assessment of certain categories of medical devices?
- Can the Agency help to fund my work?
- My medicine has been evaluated by the Agency but is not available in my country. Why not?
Please check our content on COVID-19 before sending a question about EMA’s work in response to the pandemic:
EMA is not involved in advising on travel requirements in the European Union (EU), such as vaccination, quarantine or testing for travellers.
Decisions about which COVID-19 vaccines are included, for example, in the EU Digital COVID Certificate, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.
Official information on this topic is available in all EU languages at:
Before requesting a document from EMA:
- check first if the document is available on our website;
- see the Agency's policy on Access to documents, which includes information on how to submit a request.
EMA cannot currently process all access-to-documents requests immediately.
It is dealing with requests in chronological order based on time of receipt. An access-to-documents coordinator will inform you when your procedure starts.
EMA is currently operating under business continuity measures to ensure its operational continuity during the Coronavirus disease (COVID-19) pandemic. Whilst EMA is making every effort to process all access- to-documents requests as soon as possible, due to these exceptional circumstances and to ensure a manageable flow of all access-to-documents requests from all requesters in a fair, timely and consistent way, the following approach now applies:
For more information, please refer to Q17 and Q18 of the EMA Guide on unpublished documents .
The current arrangements are in line with EMA's policy on access to documents. This states that the Agency will apply the principle of proportionality in order not to jeopardise core business tasks and its performance due to workload related to activities within Regulation (EC) No 1049/2001.
EMA collects information you provide concerning your location for the sole and exclusive purpose of processing requests for access to documents and the application of Article 2(1) of Regulation (EC) No 1049/2001. For more information, see Access to documents.
For information on how EMA uses your details, see the privacy statement concerning requests for information or access to documents .